Pautier Patricia, Kalbacher Elsa, de la Motte Rouge Thibault, Bonnetain Franck, Lesoin Anne
Département de médecine oncologique, Gustave-Roussy, Villejuif, France; Service d'oncologie médicale, CHRU de Besançon, France.
Service d'oncologie médicale, CHRU de Besançon, France.
Bull Cancer. 2017 May;104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1.
Early relapse (primary or secondary) is defined by relapse of disease less than 6 months before the last infusion of chemotherapy (with a platinum compound). There is no carcinological surgical indication. Disease should be treated with a non-platinum single agent (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine or topotecan). Bevacizumab can be added if patients have not already received it (level of proof 1, grade A).
